ZURICH-SCHLERN, Switzerland and CONCORD, Mass., December 30, 2022 (GLOBE NEWSWIRE) — Molecular Partners AG (MOLNMOLNa clinical-stage biotech company developing a new class of tailored protein drugs known as DARPin therapeutics, announced today that its Chief Executive Officer, Patrick Amstutz, Ph.D., will be attending the 41stSt annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners’ management will attend several upcoming investor events in Switzerland in January 2023.
Conference presentation details:
JP Morgan41st Annual health conference
- Wednesday, January 11, 2023 at 10:30am ET
Baader Helvea Stock Conference Switzerland
- Thursday, January 12, 2023 at 10:00 am ET
Conference participation details:
The Octavian Seminar 2023
All webcast presentations will be made available on Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of tailored protein drugs designed to address challenges not possible with current modalities. The Company has partnered with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious diseases and has compounds in various stages of clinical and pre-clinical development in multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter – @MolecularPrtnrs
For more details please contact:
Seth Lewis, Head of Investor Relations & Strategy
Concord, MA, USA
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Antonio Ligi, Head of Communications
Zurich-Schlieren, Switzerland
antonio.ligi@molecularpartners.com
Phone: +41 79 723 36 81
[ad_2]
Source story
